Critical Illness Research Group
The Critical Illness Research Group (CIRG) within the Cardiff Institute of Infection & Immunity brings together clinicians, clinical and basic scientists with an interest in the critically ill patient.
CIRG’s distinctive aim is to apply cutting-edge basic research to clinically relevant questions about the critical phase of pathologies that have direct impact on patient outcomes. The obvious overlaps with research interests represented in the existing School Institutes are seen as a positive feature of this group that will promote interdisciplinary collaborations.
Group members and benefits
Thus, CIRG’s research interest is not restricted to a particular disease or biological process. This feature of the group is reflected by its present members, who are anaesthetists and critical care clinicians, paediatricians, haemostasis specialists, wound healing experts, chemists, cell biologists, innate and T-cell immunologists, and complement biologists.
The group benefits from its strong clinical links, which facilitates access to a rich source and variety of clinical samples, and the expertise of its members across a wide spectrum of clinical and biological specialties.
All colleagues across the clinical and research communities who feel that their work may contribute to improve outcomes for critically ill patients are welcome to join CIRG, even when their research interest does not fully match CIRG’s. Joining CIRG will not preclude affiliating to other existing research groups.
Infection & Immunity
Selected recent publications by CIRG members
- Targeting the TLR Co-Receptor CD14 with TLR2-Derived Peptides Modulates Immune Responses to Pathogens.
Raby AC, Holst B, Le Bouder E, Diaz C, Ferran E, Conraux L, Guillemot JC, Coles B, Kift-Morgan A, Colmont CS, Szakmany T, Ferrara P, Hall JE, Topley N, Labéta MO, Sci Transl Med, Volume 5, 185 (May 2013) p. 185ra64
- Characterization of platelet aminophospholipid externalization reveals fatty acids as molecular determinants that regulate coagulation.
Clark SR, Thomas CP, Hammond VJ, Aldrovandi M, Wilkinson GW, Hart KW, Murphy RC, Collins PW, O'Donnell VB, Proc Natl Acad Sci U S A, Volume 110, 15 (April 2013) pp.5875-5880
- Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial.
Welton JL, Morgan MP, Martí S, Stone MD, Moser B, Sewell AK, Turton J, Eberl M, J Bone Miner Res, Volume 28, 3 (March 2013) pp.464-471
- Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.
Paixão-Cavalcante D, López-Trascasa M, Skattum L, Giclas PC, Goodship TH, de Córdoba SR, Truedsson L, Morgan BP, Harris CL, Kidney Int, Volume 82, 10 (November 2012) pp.1084-1092
- The complotype: dictating risk for inflammation and infection.
Harris CL, Heurich M, Rodriguez de Cordoba S, Morgan BP, Trends Immunol, Volume 33, 10 (October 2012) pp.513-521